Sam Fazelli

There's been all this upheaval and issues with not knowing exactly what to expect.

There's pluses and minuses here, unfortunately.

And what the FDA now needs is a solid pair of hands that gets down to the business of

looking at the safety and efficacy of drugs.

Even when the strait is reopened and the vessels start moving again and the production starts coming back, we know that it's not going to go back to pre-war levels right away.

And it's going to be very important.

to assess the damage, to see what level we can go back to.

There's been a lot of flux.

And when you get flux, and they fired, I don't know, 3,000, 3,500 individuals, a lot of old-time knowledge that's left the agency.

All of this has happened under the caretakership of Marty McCary.

not knowing exactly what to expect, having had a deal with the FDA when you go back with your data, and bringing some of these things into public conversation where it shouldn't have been done.

So there's pluses and minuses here, unfortunately, and what the FDA now needs is a solid pair of hands that gets down to the business of looking at the safety and efficacy of drugs.

There's been a lot of flux.

And when you get flux, and they fired, I don't know, 3,000, 3,500 individuals, a lot of old-time knowledge that's left the agency.

All of this has happened under the caretakership of Marty McCary.

Back in 2015-16, Lilly took a calculated risk to try this new molecule, a GLP-1 attached to it.

So they ended up with a supercharged product.

And then, of course, Novo never went down that road.

Back in 2015-16, Lilly took a calculated risk to try this new molecule, a GLP-1 attached to it.

So they ended up with a supercharged product.